drugset / Trial / NCT04637919
Safety and Immunogenicity of High-dose IN-B001 in Healthy Subjects
RandomizedSequentialQuadruple-blindPrevention
Summary
This study aims to evaluate the safety and immunogenicity of high-dose IN-B001 after administration in healthy subjects
Timeline
- Start
- 2020-12
- Primary completion
- 2021-12
- Completion
- 2021-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IN-B001 Bivalent | Vaccine | — | — |
| Subject | IN-B001 CVA16 | Vaccine | — | — |
| Subject | IN-B001 EV71 | Vaccine | — | — |